Takeda Pharmaceutical Company Limited will acquire 2,739,600 shares of treasury stock (total amount of 16,821,144,000 yen) on June 16, 2026, aiming to enhance capital efficiency and return value to shareholders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9401","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/9401-20260617-01.pdf","jir_short_summary":"Takeda Pharmaceutical Company Limited will acquire 2,739,600 shares of treasury stock (total amount of 16,821,144,000 yen) on June 16, 2026, aiming to enhance capital efficiency and return value to shareholders.","jir_summary":"### Overview of Capital Policy\nTakeda Pharmaceutical Company Limited has conducted a share buyback through the Tokyo Stock Exchange's off-auction proprietary trading system (ToSTNeT-3), aiming to improve capital efficiency and return value to shareholders. The acquisition was completed on June 17, 2026, with a total amount of 16,821,144,000 yen. This move aims to enhance stock liquidity and maximize shareholder value. The company plans to continue promoting shareholder returns as part of its capital policy.\n\n### Impact on Shareholders and Future Outlook\nThe share buyback will suppress dilution of the total issued shares and is expected to enhance shareholder value. In addition to improving capital efficiency, the company will continue to implement timely and appropriate capital policies as part of its shareholder return strategy. It is also expected to consider ongoing share acquisitions and revisions to dividend policies while assessing market conditions and investment opportunities. For investors, increased capital efficiency and continuous shareholder returns will be key points.","jir_financial_highlights":"Total number of shares acquired: 2,739,600 shares (Unknown)\nTotal acquisition cost: 16,821,144,000 yen (Unknown)\nAcquisition date: June 17, 2026 (Unknown)","jir_category":"","jir_hashtags":"#TakedaPharmaceuticalCompanyLimited, #ShareBuyback, #JapaneseStocks","jir_key_figures":"Number of treasury shares acquired: 2,739,600 shares\nTotal amount acquired: 16,821,144,000 yen\nAcquisition date: June 17, 2026","jir_meta_title":"\u3010Takeda Pharmaceutical Company Limited\u3011Share Buyback | June 2026","jir_meta_description":"Takeda Pharmaceutical Company Limited acquired 2,739,600 shares of treasury stock in June 2026, promoting capital efficiency and shareholder returns. Detailed information explained.","jir_og_title":"\u3010Takeda\u3011Share Buyback | June 2026","jir_og_description":"Takeda Pharmaceutical Company Limited acquired 2,739,600 shares of treasury stock, strengthening capital efficiency and shareholder returns. Latest capital policy details explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7600,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-65159","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n